RE-BVS – Piemonte Repository

Sfoglia per AUTORE
SANTINI D
Collezione ASL Cuneo 2

Items : 6

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies. in ESMO open / ESMO Open. 2024 Jul;9(7):103484. doi: 10.1016/j.esmoop.2024.103484. Epub 2024 Jun 19.

2024
ASL Cuneo 2
ASL Asti
AOU Alessandria
AOU Città della Salute di Torino

Santini D; Bertoldo F; Tucci M; Berruti A; Pantano F; Procopio G; Di Maio M; Valsecchi AA; De Giorgi U; Cursano MC;

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w.

2024
ASL Cuneo 2
AOU Novara

Mosca A; Morelli F; Bisonni R; Bamias A; Santini D; Herchhorn D; Kanesvaran R; Inman E; Caitano M; Messina C; Martignetti A; Kopecky J; Milella M; Procopio G; Abahssain H; Roviello G; Kopp RM; Bassanelli M; Fernandez M; Cutuli HJ; Grillone F; Aceituno LG; Seront E; de Carvalho Fernandes R; Nogueira L; Mennitto A; Dauster B; Monteiro FSM; Barillas A; et alii...

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. in Journal of the National Cancer Institute / J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061.

2023
ASL Cuneo 2

Cantini L; Paoloni F; Pecci F; Spagnolo F; Genova C; Tanda ET; Aerts S; Rebuzzi SE; Fornarini G; Zoratto F; Fancelli S; Lupi A; Della Corte CM; Parisi A; Bennati C; Ortega C; Atzori F; Piovano PL; Orciuolo C; De Tursi M; Ghidini M; Botticelli A; Scagnoli S; Belluomini L; Leporati R; Veccia A; Di Giacomo AM; Festino L; Cortinovis D; et alii...

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). in International journal of molecular sciences / Int J Mol Sci. 2023 Jan 6;24(2):1096. doi: 10.3390/ijms24021096.

2023
ASL Cuneo 2

Stellato M; Buti S; Maruzzo M; Bersanelli M; Pierantoni F; De Giorgi U; Di Napoli M; Iacovelli R; Vitale MG; Ermacora P; Malgeri A; Maiorano BA; Prati V; Mennitto A; Cavo A; Santoni M; Carella C; Fratino L; Procopio G; Verzoni E; Santini D;

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. in Journal of translational medicine / J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Messina M; Caffo O; Di Napoli M; Atzori F; Santini D; Soto Parra HJ; Prati V; Cortellini A; Santoni M; Sorarù M; Mollica V; Panni S; Ricotta R; Pipitone S; Fratino L; Boccardo F; Milella M; Procopio G; Naglieri E; Fantinel E; Zucali PA; Galli L; Chiellino S; Basso U; De Giorgi U; Maruzzo M; Damassi A; Fornarini G; Gandini A; et alii...

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis. in Frontiers in oncology / Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Nolè F; Prati G; Morelli F; Messina M; Caffo O; Di Napoli M; Atzori F; Soto Parra HJ; Prati V; Cortellini A; Sorarù M; Santoni M; Massari F; Panni S; Ricotta R; Sabbatini R; Fratino L; Boccardo F; Milella M; Procopio G; Carella C; Fantinel E; Zucali PA; Galli L; Pedrazzoli P; De Giorgi U; Maruzzo M; Santini D; Stellato M; et alii...